Cambridge, UK;  1st October 2020.

Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”)  the specialist gastrointestinal (GI) pharmaceutical company focused on acquiring, developing and commercializing therapies that address unmet patient needs and rare diseases will attend UEG (United European Gastroenterology) Week, Virtual Congress from October 11 – 13, 2020.

This Congress is a premier venue for leading companies in the field of digestive health to connect, showcase and discover the latest data, research and therapies.

To request a meeting please email or 

About Atlantic Healthcare

Atlantic Healthcare plc ( is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.

The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders.

Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products itself in the U.S. and Europe and through partnerships and licensing with established pharmaceutical companies in the rest of the world.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.

For more information about Atlantic Healthcare, investment, alicaforsen or renzapride, please contact:

Adam Michael (Head of Communications)
+44 1799 512 055
+44 777 588 1813


Consilium Strategic Communications
Mary-Jane Elliott / Matthew Neal
+44 20 3709 5700